Total Payments
$81,418
2023 Payments
$1,400
Companies
4
Transactions
122
Medicare Patients
194
Medicare Billing
$24,456
Payment Breakdown by Category
Other$43,680 (53.6%)
Research$36,009 (44.2%)
Food & Beverage$1,417 (1.7%)
Education$280.35 (0.3%)
Travel$31.75 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,680 | 47 | 53.6% |
| Unspecified | $36,009 | 28 | 44.2% |
| Food and Beverage | $1,417 | 15 | 1.7% |
| Education | $280.35 | 31 | 0.3% |
| Travel and Lodging | $31.75 | 1 | 0.0% |
Payments by Type
General
$45,409
94 transactions
Research
$36,009
28 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $75,868 | 117 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $5,422 | 3 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $116.09 | 1 | $0 (2017) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,400 | 1 | PFIZER INC. ($1,400) |
| 2022 | $9,080 | 4 | PFIZER INC. ($9,080) |
| 2021 | $13,182 | 17 | PFIZER INC. ($13,170) |
| 2020 | $6,980 | 7 | PFIZER INC. ($6,980) |
| 2019 | $20,194 | 30 | PFIZER INC. ($20,194) |
| 2018 | $23,038 | 45 | PFIZER INC. ($23,006) |
| 2017 | $7,544 | 18 | NOVARTIS PHARMACEUTICALS CORPORATION ($5,389) |
All Payment Transactions
122 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/06/2023 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $1,400.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/27/2022 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/19/2022 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/18/2022 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $1,900.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 03/10/2022 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/10/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/21/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/21/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 07/09/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/09/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $1,400.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/08/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/08/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/08/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/08/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $620.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/12/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 05/11/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/17/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/17/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/17/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/17/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/28/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/12/2020 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $620.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/02/2020 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 04/28/2020 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TALAZOPARIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $30,620 | 27 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $5,389 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 45 | 87 | $16,451 | $4,516 |
| 2022 | 2 | 37 | 74 | $16,068 | $4,893 |
| 2021 | 3 | 58 | 97 | $27,443 | $7,119 |
| 2020 | 2 | 54 | 104 | $38,329 | $7,929 |
Total Patients
194
Total Services
362
Medicare Billing
$24,456
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 19 | 48 | $8,208 | $2,450 | 29.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 24 | $6,418 | $1,692 | 26.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 14 | 15 | $1,825 | $373.23 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 17 | 43 | $10,969 | $3,347 | 30.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 20 | 31 | $5,099 | $1,546 | 30.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 20 | 40 | $9,743 | $2,748 | 28.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 13 | 26 | $12,768 | $2,698 | 21.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 25 | 31 | $4,932 | $1,673 | 33.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 19 | 57 | $27,261 | $5,165 | 18.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 35 | 47 | $11,068 | $2,764 | 25.0% |
About Dr. Jennifer Litton, M.D
Dr. Jennifer Litton, M.D is a Medical Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821196759.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jennifer Litton, M.D has received a total of $81,418 in payments from pharmaceutical and medical device companies, with $1,400 received in 2023. These payments were reported across 122 transactions from 4 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($43,680).
As a Medicare-enrolled provider, Litton has provided services to 194 Medicare beneficiaries, totaling 362 services with total Medicare billing of $24,456. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Houston, TX
- Active Since 09/21/2006
- Last Updated 12/03/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1821196759
Products in Payments
- TALZENNA (Drug) $73,030
- AFINITOR (Drug) $5,389
- IBRANCE (Drug) $430.37
- LYNPARZA (Drug) $116.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Houston
Roy Herbst, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Putao Cen, Md, MD
Medical Oncology — Payments: $817,580
Medical Oncology $817,580
Hagop Kantarjian, Md, MD
Medical Oncology — Payments: $740,835
Medical Oncology $740,835
Dr. Matthew Ellis, Md Phd, MD PHD
Medical Oncology — Payments: $714,994
Medical Oncology $714,994
Eleni Efstathiou, M.d, M.D
Medical Oncology — Payments: $600,908
Medical Oncology $600,908
Srdan Verstovsek, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $577,763
Medical Oncology $577,763